Redwood Investment Management LLC Sells 5,967 Shares of Merck & Co., Inc. $MRK

Redwood Investment Management LLC lessened its position in Merck & Co., Inc. (NYSE:MRK) by 54.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,896 shares of the company’s stock after selling 5,967 shares during the period. Redwood Investment Management LLC’s holdings in Merck & Co., Inc. were worth $589,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Ballast Advisors LLC bought a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $196,000. Sapient Capital LLC increased its position in Merck & Co., Inc. by 63.4% in the 1st quarter. Sapient Capital LLC now owns 16,402 shares of the company’s stock valued at $1,987,000 after acquiring an additional 6,365 shares during the period. Vilga Financial Planning LLC bought a new position in shares of Merck & Co., Inc. during the first quarter valued at $232,000. LFG Wealth Partners LLC raised its stake in shares of Merck & Co., Inc. by 4.8% during the first quarter. LFG Wealth Partners LLC now owns 10,282 shares of the company’s stock valued at $1,237,000 after acquiring an additional 469 shares during the last quarter. Finally, Dakota Community Bank & Trust NA lifted its holdings in shares of Merck & Co., Inc. by 5.4% during the first quarter. Dakota Community Bank & Trust NA now owns 3,832 shares of the company’s stock worth $461,000 after purchasing an additional 197 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. Adjusted loss per share of $0.13 was also better than the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth engine, while the newer injectable version of the cancer treatment exceeded Wall Street expectations by more than $200 million. Strength in oncology and other newer products helped support the improved sales outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its full-year 2026 revenue forecast to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus. Management also highlighted regulatory, clinical and pipeline milestones that could support longer-term growth. MRK Q2 Earnings and Sales Beat Estimates, 2026 Sales View Raised
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate, because of charges associated with the acquisition of Terns Pharmaceuticals. The resulting earnings pressure offsets part of the benefit from the stronger sales outlook. Merck hikes revenue outlook but cuts profit guidance due to deal charges

Analyst Ratings Changes

Several brokerages recently weighed in on MRK. Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Morgan Stanley lifted their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Finally, BMO Capital Markets upped their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $128.28 on Wednesday. The firm has a market cap of $316.83 billion, a PE ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05. The business’s 50 day moving average price is $123.45 and its two-hundred day moving average price is $118.78. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.